Tresiba Cost in California 2026: What You Will Pay and How to Lower It

What Does Tresiba Actually Cost in California in 2026?

Tresiba's manufacturer list price sits near $510 per month in 2026, but that figure almost never reflects what a California patient actually pays at the pharmacy counter. Cash-pay programs, insurance tiers, and Medi-Cal each create very different out-of-pocket numbers, sometimes differing by more than $475 per month for the same pen device.

Novo Nordisk set the wholesale acquisition cost (WAC) for Tresiba FlexTouch at approximately $510 per month for a standard supply of five 3-mL pens (300 units each). The FDA-approved label, available at FDA AccessData, confirms the 100 units/mL and 200 units/mL concentrations available in the United States. [1]

Retail cash-pay prices across California in 2026 average near $35 per month when a GoodRx or NeedyMeds coupon is applied at chains including CVS, Walgreens, Rite Aid, and Costco Pharmacy. [2] Prices vary by zip code. Pharmacies in Los Angeles, San Diego, and San Francisco tend to offer competitive coupon pricing, while rural Northern California pharmacies may show slightly higher baseline costs before coupons are applied.

Patients enrolled in commercial insurance with Tresiba on a preferred Tier 2 position typically pay a $25 to $80 copay per month, depending on their plan's formulary. Non-preferred Tier 3 placement pushes that copay to $80 to $150 per month before any savings card offsets. The ADA Standards of Medical Care in Diabetes 2024 recommend that clinicians consider total out-of-pocket insulin cost as part of prescribing decisions, noting that affordability directly affects adherence. [3]

The DEVOTE trial (N=7,637, published in the New England Journal of Medicine in 2017) established that insulin degludec produced a significantly lower rate of severe hypoglycemia compared with glargine U-100 (hazard ratio 0.60; 95% CI 0.48 to 0.76; P<0.001 for superiority), which supports the clinical rationale for choosing degludec over less expensive basal insulins when hypoglycemia risk is high. [4] That safety advantage may justify higher insurance tiers or prior authorization effort for appropriate patients.

Does Medi-Cal Cover Tresiba in California?

Medi-Cal covers Tresiba for both type 1 and type 2 diabetes, but prior authorization (PA) is required. Approval is generally granted when a prescriber documents a clinical reason that a preferred basal insulin such as glargine (Lantus, Basaglar) or detemir (Levemir) is not appropriate. PA approvals typically run 12 months before renewal is needed.

The Medi-Cal Rx formulary classifies insulin degludec as a non-preferred diabetic agent requiring PA. [5] The California Department of Health Care Services (DHCS) published updated pharmacy policy in late 2023 indicating that basal insulin PA criteria include documented hypoglycemia on a preferred agent, renal impairment affecting insulin clearance, or documented adherence benefit from a once-daily ultra-long-acting profile. [6]

Prescribers submitting a PA for Medi-Cal should include: HbA1c history, prior basal insulin trial and outcome, and any documented severe hypoglycemia events. The Endocrine Society Clinical Practice Guideline on Insulin Therapy notes that insulin degludec's half-life of approximately 25 hours produces a flatter pharmacodynamic profile than glargine U-100, reducing nocturnal hypoglycemia risk, which is a clinically supported PA argument. [7]

Medi-Cal managed care plans (such as L.A. Care or Health Net Community Solutions) may have slightly different PA step-edit requirements than fee-for-service Medi-Cal. Confirm formulary status directly with the managed care organization before submitting a PA to avoid denial on procedural grounds.

Patients who are dually eligible for Medicare and Medi-Cal should check Medicare Part D first. Medicare Part D plans are required by CMS to cover at least one basal insulin per formulary category, and some plans list degludec at a preferred tier. The CMS Medicare Prescription Drug Benefit Manual governs these formulary rules. [8]

Which Private Insurance Plans Cover Tresiba in California?

Most major California commercial carriers cover Tresiba at Tier 2 or Tier 3, depending on their annual formulary review cycle. Blue Shield of California, Anthem Blue Cross, and Health Net each placed degludec on formulary in their 2025 and 2026 plan years, though tier position varies by product line.

The American Diabetes Association's 2024 Standards recommend individualized insulin selection, stating: "The choice of insulin regimen must be individualized based on the patient's metabolic needs, lifestyle, hypoglycemia risk, and cost." [3] That language gives prescribers documented clinical support when appealing a Tier 3 placement or requesting exceptions.

Covered California marketplace plans follow ACA formulary rules, which require coverage of at least one insulin per class. Plans are not required to cover every brand. If your Covered California plan lists only glargine as preferred, a Tier Exception request citing DEVOTE hypoglycemia data [4] and the Endocrine Society guideline [7] is one documented path to reduced cost-sharing for degludec.

Employer-sponsored plans operating under ERISA may differ. Always verify your specific plan's Summary of Benefits and Coverage (SBC) before assuming coverage.

How Does the Novo Nordisk Savings Card Work in California?

The Novo Nordisk Patient Assistance and savings card programs reduce out-of-pocket cost for commercially insured patients and, in some cases, uninsured patients. The savings card (marketed under the "My$99Insulin" and Novo Nordisk Savings Card programs) has historically capped monthly cost at $99 per prescription for eligible patients, and a separate $35/month cap has applied under some program iterations.

Eligibility typically requires: commercially insured status (not Medicare, Medicaid, or any federally funded program), residence in the United States, and a valid prescription. California residents can enroll at NovoCare, Novo Nordisk's patient support platform. The FDA's guidance on manufacturer copay assistance clarifies that these programs are permissible under federal law but cannot be applied to government-funded insurance. [9]

For uninsured California patients who do not qualify for Medi-Cal, Novo Nordisk's NovoCare Patient Assistance Program (PAP) provides Tresiba at no cost to patients meeting income criteria (generally at or below 400% of the federal poverty level). Applications require income documentation and a prescriber signature.

The Novo Nordisk savings card does not stack with Medi-Cal or Medicare Part D. If you are Medi-Cal eligible, the PA route described above is your correct path, not the manufacturer savings card.

Is Compounded Insulin Degludec Legal in California?

Compounded insulin degludec is legal in California when dispensed by a 503A pharmacy licensed by the California State Board of Pharmacy, but several conditions must be met. The pharmacy must compound pursuant to a valid patient-specific prescription, the drug must not be on the FDA's list of withdrawn or removed drugs for safety reasons, and the compounded preparation must not be a copy of a commercially available product without a documented clinical difference.

The FDA's current policy on compounded drugs describes 503A pharmacies as operating under state board oversight with limited interstate distribution rights. [10] California's 503A pharmacies are regulated by the California State Board of Pharmacy under Business and Professions Code Section 4126. [11]

The clinical and regulatory question for insulin degludec specifically is whether a compounded preparation constitutes an "essentially a copy" of Tresiba. FDA guidance issued in 2018 states that a compounded drug is "essentially a copy" if it is the same as a commercially available product and there is no difference in active ingredient, route, dosage form, or strength that produces a clinical difference. [12] A prescriber who documents a specific clinical need (e.g., a customized concentration for a patient requiring very low volume doses, or removal of a particular excipient) may support the case that the preparation is not an impermissible copy.

The practical result: California patients with a valid 503A prescription from a licensed prescriber may obtain compounded insulin degludec at significantly reduced or zero drug cost. The compounding pharmacy assumes manufacturing risk, and potency and sterility standards are enforced by state inspection rather than FDA pre-market review. Patients should confirm that their chosen compounding pharmacy holds an active California State Board of Pharmacy license before transferring any prescription.

The U.S. Pharmacopeia Chapter 797 sets sterility standards for compounded sterile preparations, which insulin injections fall under. [13] Any California 503A pharmacy compounding insulin degludec must comply with USP 797 as incorporated into California law under 16 California Code of Regulations Section 1751.

Can a Telehealth Provider in California Prescribe Tresiba?

Yes. California law allows telehealth prescribing of Tresiba when the prescriber holds a valid California DEA registration (for controlled substances, which insulin is not), a California medical license, and has established a valid patient-provider relationship meeting the standard-of-care requirements under Business and Professions Code Section 2290.5.

Insulin degludec is not a controlled substance, which simplifies telehealth prescribing compared to, for example, testosterone or GLP-1 weight-loss medications in some states. A California-licensed prescriber conducting a synchronous video visit may issue a prescription for Tresiba that is valid at any California-licensed pharmacy. [14]

The California Medical Board's Telehealth Policy confirms that the standard of care for telehealth encounters equals that of in-person visits, meaning the prescriber must conduct an adequate history and physical assessment before initiating insulin therapy. [15] For basal insulin initiation, this assessment should include review of current HbA1c, fasting glucose logs, renal function (eGFR), and hypoglycemia history.

Telehealth platforms operating in California that offer endocrinology or diabetes management services include both specialty and primary care models. Prescriptions issued via these platforms are transmitted electronically to a pharmacy of the patient's choice. There is no California-specific restriction on which pharmacy may fill a telehealth-issued Tresiba prescription, including mail-order pharmacies licensed in California.

What Is the Cheapest Way to Get Tresiba in California?

The lowest documented acquisition cost for Tresiba in California depends on insurance status and eligibility for assistance programs. Here is a structured breakdown.

Medi-Cal eligible patients: Apply for Medi-Cal first. If your household income is at or below 138% of the federal poverty level, Medi-Cal is likely the lowest-cost option. PA approval eliminates out-of-pocket drug cost entirely in most Medi-Cal plans. [5]

Commercially insured patients: Apply the Novo Nordisk savings card at the pharmacy counter. This may reduce cost to $35 per month or lower depending on the current program terms. Verify at NovoCare before the prescription is filled. [9]

Uninsured patients: Use GoodRx or a similar drug pricing platform. Cash-pay prices in California average near $35 per month with coupon in 2026. [2] If income qualifies, apply to the NovoCare PAP for free drug. The NeedyMeds database lists both manufacturer and independent assistance programs for insulin degludec. [16]

503A compounded insulin degludec: If a clinician documents a valid clinical reason for compounding, a California 503A pharmacy may dispense compounded insulin degludec at minimal or no drug cost. This is the lowest-cost path for eligible patients, but requires active prescriber involvement and pharmacy verification.

Insulin cap legislation context: California's AB 2449 (2022) capped monthly out-of-pocket insulin cost at $35 for state-regulated health plans. [17] This cap applies to commercially insured patients on state-regulated plans, not self-insured employer plans under ERISA. Confirm whether your plan is state-regulated or federally governed before relying on this cap.

The CDC National Diabetes Statistics Report 2024 estimates that 3.2 million Californians have diagnosed diabetes, making insulin affordability one of the state's highest-volume pharmaceutical access issues. [18]

Tresiba Clinical Profile: Why Providers Choose Degludec Over Alternatives

Understanding why a clinician may specifically prescribe Tresiba rather than a lower-cost biosimilar glargine helps patients make the case for PA approvals and insurance exceptions.

Insulin degludec forms soluble multi-hexamer chains after subcutaneous injection. This structure produces a half-life near 25 hours and a duration of action exceeding 42 hours, compared with approximately 20 to 24 hours for glargine U-100. [7] The flatter pharmacokinetic profile reduces day-to-day glucose variability.

DEVOTE (N=7,637, NEJM 2017) was a double-blind, treat-to-target cardiovascular outcomes trial comparing degludec to glargine U-100 in patients with type 2 diabetes at high cardiovascular risk. Degludec was non-inferior to glargine on major adverse cardiovascular events (MACE: 8.5% vs. 9.3%; HR 0.91; 95% CI 0.78 to 1.06). Severe hypoglycemia occurred in significantly fewer degludec-treated patients (4.9% vs. 6.6%; HR 0.60; P<0.001 for superiority). [4] The trial enrolled patients from 20 countries and ran for a median of 2.0 years.

A 2019 meta-analysis in Diabetes Care (N=12 randomized controlled trials, 8,827 patients) found that insulin degludec reduced nocturnal confirmed hypoglycemia by 36% compared with glargine U-100 (RR 0.64; 95% CI 0.56 to 0.73). [19]

The Endocrine Society guideline states: "We recommend insulin degludec or insulin glargine U-300 over other basal insulins for patients with type 2 diabetes who are at high risk of hypoglycemia." [7] That recommendation provides direct, quotable clinical support for PA submissions in California.

The FDA-approved starting dose for Tresiba in insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily. In type 1 diabetes, degludec comprises approximately one-third to one-half of total daily insulin dose, with the remainder delivered as rapid-acting insulin. Dose titration follows fasting glucose targets per the treating clinician's protocol. [1]

Are There Other California Discount Programs for Tresiba?

Several California-specific and national programs supplement the Novo Nordisk savings card.

Covered California cost-sharing reductions (CSRs): Patients enrolling in Silver-tier Covered California plans with household income between 100% and 250% of the federal poverty level receive CSRs that lower deductibles and out-of-pocket maximums. [20] If Tresiba is on the plan's formulary, CSRs reduce the effective per-prescription cost significantly.

California's Insulin Affordability Cap (AB 2449): As noted, state-regulated commercial plans cap monthly insulin out-of-pocket cost at $35. This cap covers FDA-approved insulin brands including Tresiba. Plans regulated by ERISA (most large employer plans) are not subject to this cap.

County indigent care programs: Los Angeles County's My Health LA program and similar county programs in Alameda, San Diego, and Sacramento provide pharmacy benefits to uninsured residents who do not qualify for Medi-Cal. Coverage of brand-name insulin varies by county formulary.

340B program: Federally qualified health centers (FQHCs) and other 340B-eligible providers in California can acquire Tresiba at the 340B ceiling price, which is substantially below WAC. Patients receiving care at an FQHC may access Tresiba at reduced or no cost through the 340B program. The HRSA 340B database lists eligible California providers. [21]

GoodRx Gold and similar subscription programs: A GoodRx Gold membership ($9.99/month in 2026) may produce lower coupon prices at specific California pharmacies than the free GoodRx tier. Check both tiers before submitting the coupon at the counter. [2]

The ADA's insulin access resources page maintains an updated list of manufacturer and independent programs for uninsured and underinsured patients. [3]